Carisma Therapeutics Inc. (CARM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
The latest price target for CARISMA Therapeutics (OTCID:CARM) was reported by D. Boral Capital on August 8, 2025. The analyst firm set a price target for $1.00 expecting CARM to rise to within 12 ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Carisma Therapeutics ( (CARM)) has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback